Be it Resolved that Endolumenal Therapies, Including Full Thickness Recection, Will Make Segmental Resection Obsolete for Primary Treatment of Gastrointestinal Neoplasia
Presented by Lee Swanstrom, MD and Bruce Schirmer, MD at the SAGES 2014 Meeting; The Great Presidential Debates of 2014 Dr. Lee Swantsrom’s argument begins: Endoluminal therapies will be the future of early GI cx tx–1:55 disclosures–3:00 ESD–4:00 case 1 example–5:40 case 2 example–7:20 citation–12:17 https:// Keyword(s): abdominal cavity, adenocarcinoma, advanced cx, adverse histopathological findings, […]
Open Thoracic Approach is Preferred: Jeffrey Peters, M.D.
Hernia Debates Panel: What Has Happened and What Do We Have to Do? Keyword(s): biologic mesh, biologic prosthesis, failure, GPEH, lap management, lap repair, mesh erosion, Nissen fundoplication, open approach, PEH, prosthetic mesh, QOL, recurrence rate, reflux, transabdominal, transmural migration, Type III HH
Should Investigational Procedures be Reimbursed? Debates: S.D. Wexner, M.D. and J.H. Peters, M.D.
SAGES Presidential Debates Keyword(s): clinical trials, device manufacturers, ethics, industry, investigational procedures, minimal access surgery, NIH, reimbursement, surgical organizations, third party payers
Should Investigational Procedures be Reimbursed? No: Jeffrey H. Peters, M.D.
SAGES Presidential Debates citation–2:35 https://www.ncbi.nlm.nih.gov/pubmed/16174691 Keyword(s): biomedical research, healthcare industry, insurance industry, medical device industry, NIH, pharmaceutical industry, reimbursement
The Strategy for Screening, Surveillance of Barrett’s Esophagus: Jeffrey Peters, M.D.
Barrett’s Debate: How to Follow, How to Treat? citations–11 sec https://www.ncbi.nlm.nih.gov/pubmed/16860065 https://www.ncbi.nlm.nih.gov/pubmed/15476150 problems with BE screening–4:32 citation–6:20 https://www.ncbi.nl Keyword(s): ACG, adenocarcinoma, ASGE guideline, BE, Cleveland Clinic BE registry, cost-effectiveness, cost-effectiveness model, dysplasia, endoscopic bx, endoscopy, esophageal cx, GERD, HGD, LGD, neoplasia, screening, surveillance, UE